Adoptive Transfer of Autologous, HER2-specific, Cytotoxic T Lymphocytes for the Treatment of HER2-overexpressing Breast Cancer

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2007 Jul 25

PMID 17646988

Citations 81

Authors

Helga Bernhard

Julia Neudorfer

Kerstin Gebhard

Heinke Conrad

Christine Hermann

Jorg Nahrig

Falko Fend

Wolfgang Weber

Dirk H Busch

Christian Peschel

Affiliations

Soon will be listed here.

Abstract

The human epidermal growth factor receptor 2 (HER2) has been targeted as a breast cancer-associated antigen by immunotherapeutical approaches based on HER2-directed monoclonal antibodies and cancer vaccines. We describe the adoptive transfer of autologous HER2-specific T-lymphocyte clones to a patient with metastatic HER2-overexpressing breast cancer. The HLA/multimer-based monitoring of the transferred T lymphocytes revealed that the T cells rapidly disappeared from the peripheral blood. The imaging studies indicated that the T cells accumulated in the bone marrow (BM) and migrated to the liver, but were unable to penetrate into the solid metastases. The disseminated tumor cells in the BM disappeared after the completion of adoptive T-cell therapy. This study suggests the therapeutic potential for HER2-specific T cells for eliminating disseminated HER2-positive tumor cells and proposes the combination of T cell-based therapies with strategies targeting the tumor stroma to improve T-cell infiltration into solid tumors.

Citing Articles

Integrating immunotherapy with conventional treatment regime for breast cancer patients- an amalgamation of armamentarium.

Nandi D, Sharma D Front Immunol. 2024; 15:1477980.

PMID: 39555066 PMC: 11563812. DOI: 10.3389/fimmu.2024.1477980.

Nanotechnology in the development of small and large molecule tyrosine kinase inhibitors and immunotherapy for the treatment of HER2-positive breast cancer.

Ejigah V, Mandala B, Akala E J Cancer Metastasis Res. 2024; 4(2):6-22.

PMID: 38966076 PMC: 11223443.

Update on current and new potential immunotherapies in breast cancer, from bench to bedside.

Alaluf E, Shalamov M, Sonnenblick A Front Immunol. 2024; 15:1287824.

PMID: 38433837 PMC: 10905744. DOI: 10.3389/fimmu.2024.1287824.

Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies.

Goddard E, Linde M, Srivastava S, Klug G, Shabaneh T, Iannone S Cancer Cell. 2024; 42(1):119-134.e12.

PMID: 38194912 PMC: 10864018. DOI: 10.1016/j.ccell.2023.12.011.

Microengineered In Vitro Assays for Screening and Sorting Manufactured Therapeutic T Cells.

Muhuri A, Alapan Y, Camargo C, Thomas S J Immunol. 2024; 212(2):199-207.

PMID: 38166247 PMC: 10783858. DOI: 10.4049/jimmunol.2300488.

References

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

Fleming G, Meropol N, Rosner G, Hollis D, Carson 3rd W, Caligiuri M . A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002; 8(12):3718-27. View

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

Braun S, Vogl F, Naume B, Janni W, Osborne M, Coombes R . A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353(8):793-802. DOI: 10.1056/NEJMoa050434. View

Lee P, Yee C, Savage P, Fong L, Brockstedt D, Weber J . Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999; 5(6):677-85. DOI: 10.1038/9525. View

zum Buschenfelde C, Metzger J, Hermann C, Nicklisch N, Peschel C, Bernhard H . The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J Immunol. 2001; 167(3):1712-9. DOI: 10.4049/jimmunol.167.3.1712. View

Qin Z, Blankenstein T . A cancer immunosurveillance controversy. Nat Immunol. 2003; 5(1):3-4. DOI: 10.1038/ni0104-3. View

Neudorfer J, Schmidt B, Huster K, Anderl F, Schiemann M, Holzapfel G . Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods. 2007; 320(1-2):119-31. DOI: 10.1016/j.jim.2007.01.001. View

Padera T, Stoll B, Tooredman J, Capen D, Tomaso E, Jain R . Pathology: cancer cells compress intratumour vessels. Nature. 2004; 427(6976):695. DOI: 10.1038/427695a. View

10.

Blankenstein T . The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol. 2005; 17(2):180-6. DOI: 10.1016/j.coi.2005.01.008. View

11.

Zum Buschenfelde C, Hermann C, Schmidt B, Peschel C, Bernhard H . Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 2002; 62(8):2244-7. View

12.

Knabel M, Franz T, Schiemann M, Wulf A, Villmow B, Schmidt B . Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med. 2002; 8(6):631-7. DOI: 10.1038/nm0602-631. View

13.

Zhou J, Dudley M, Rosenberg S, Robbins P . Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J Immunol. 2004; 173(12):7622-9. PMC: 2174603. DOI: 10.4049/jimmunol.173.12.7622. View

14.

Rongcun Y, Salazar-Onfray F, Charo J, Malmberg K, Evrin K, Maes H . Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol. 1999; 163(2):1037-44. View

15.

Gattinoni L, Klebanoff C, Palmer D, Wrzesinski C, Kerstann K, Yu Z . Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005; 115(6):1616-26. PMC: 1137001. DOI: 10.1172/JCI24480. View

16.

Walker B, Flexner C, Fisher L, Paradis T, Aldovini A, Young R . Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1989; 86(23):9514-8. PMC: 298527. DOI: 10.1073/pnas.86.23.9514. View

17.

Jager E, Nagata Y, Gnjatic S, Wada H, STOCKERT E, Karbach J . Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A. 2000; 97(9):4760-5. PMC: 18306. DOI: 10.1073/pnas.97.9.4760. View

18.

Muller M, Grunebach F, Nencioni A, Brossart P . Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol. 2003; 170(12):5892-6. DOI: 10.4049/jimmunol.170.12.5892. View

19.

Carson W, Parihar R, Lindemann M, Personeni N, Dierksheide J, Meropol N . Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol. 2001; 31(10):3016-25. DOI: 10.1002/1521-4141(2001010)31:10<3016::aid-immu3016>3.0.co;2-j. View

20.

Robbins P, Dudley M, Wunderlich J, El-Gamil M, Li Y, Zhou J . Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004; 173(12):7125-30. PMC: 2175171. DOI: 10.4049/jimmunol.173.12.7125. View